TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

04 Apr 2022 15:05:00 By Nasdaq GlobeNewswire

Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201

21 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

03 Mar 2022 15:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference

28 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer

06 Jan 2022 06:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference

03 Jan 2022 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

15 Nov 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021

12 Nov 2021 06:05:00 By Nasdaq GlobeNewswire

Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501

09 Nov 2021 15:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experience 2021

18 Oct 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

05 Oct 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors

28 Sep 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

08 Sep 2021 06:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

02 Sep 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

16 Aug 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

03 Aug 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

24 Jun 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH

14 Jun 2021 06:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH

13 Jun 2021 16:00:00 By Nasdaq GlobeNewswire

Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Conference Call Series

19 May 2021 16:00:00 By Nasdaq GlobeNewswire